Blue Trust Inc. Boosts Stake in Cellebrite DI Ltd. $CLBT

Blue Trust Inc. lifted its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 7.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,223 shares of the company’s stock after purchasing an additional 1,497 shares during the quarter. Blue Trust Inc.’s holdings in Cellebrite DI were worth $356,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also bought and sold shares of CLBT. Signaturefd LLC raised its position in Cellebrite DI by 68.3% in the 2nd quarter. Signaturefd LLC now owns 2,019 shares of the company’s stock worth $32,000 after buying an additional 819 shares during the last quarter. Assetmark Inc. purchased a new position in shares of Cellebrite DI during the first quarter valued at approximately $33,000. Catalyst Capital Advisors LLC purchased a new position in shares of Cellebrite DI during the first quarter valued at approximately $51,000. Virtus Advisers LLC purchased a new stake in Cellebrite DI during the 1st quarter valued at $63,000. Finally, Hennessy Advisors Inc. purchased a new stake in Cellebrite DI during the 2nd quarter valued at $83,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Stock Up 2.4%

Shares of CLBT opened at $19.56 on Tuesday. The business has a 50-day simple moving average of $16.83 and a two-hundred day simple moving average of $16.92. The stock has a market cap of $4.68 billion, a price-to-earnings ratio of -25.74, a PEG ratio of 3.47 and a beta of 1.29. Cellebrite DI Ltd. has a 52 week low of $13.10 and a 52 week high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.01. The company had revenue of $113.28 million during the quarter, compared to analyst estimates of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The firm’s quarterly revenue was up 18.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Lake Street Capital decreased their target price on shares of Cellebrite DI from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Friday, August 15th. Needham & Company LLC reduced their price objective on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, August 14th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Cellebrite DI in a research report on Wednesday, October 8th. JPMorgan Chase & Co. upped their price target on shares of Cellebrite DI from $20.00 to $23.00 and gave the company an “overweight” rating in a research report on Wednesday, September 24th. Finally, Wall Street Zen raised shares of Cellebrite DI from a “hold” rating to a “buy” rating in a research report on Friday, September 26th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $21.75.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.